Format

Send to

Choose Destination
J Affect Disord. 2018 Jan 1;225:545-551. doi: 10.1016/j.jad.2017.08.081. Epub 2017 Aug 30.

Clinical experience using intranasal ketamine in the longitudinal treatment of juvenile bipolar disorder with fear of harm phenotype.

Author information

1
Juvenile Bipolar Research Foundation, 277 Martine Avenue, Suite 226 White Plains, NY 10601, United States; Department of Psychiatry, Albert Einstein College of Medicine, New York, United States. Electronic address: demitri@optonline.net.
2
Advanced Signal Analysis and Processing, 2360 Sterling Creek Pkwy, Oviedo, FL 32766, United States.
3
Juvenile Bipolar Research Foundation, 277 Martine Avenue, White Plains, NY 10601, United States.
4
Department of Psychiatry Cornell-Weil Medical College of Medicine, United States.
5
Developmental Biopsychiatry Research Program, McLean Hospital, Department of Psychiatry, Harvard Medical School, United States.

Abstract

OBJECTIVES:

Fear of Harm (FOH) is a pediatric onset phenotype of bipolar disorder (BD) characterized by BD plus treatment resistance, separation anxiety, aggressive obsessions, parasomnias, and thermal dysregulation. Intranasal ketamine (InK) in 12 youths with BD-FOH produced marked improvement during a two-week trial. Here we report on the open effectiveness and safety of InK in maintenance treatment of BD-FOH from the private practice of one author.

METHODS:

As part of a chart review, patients 18 years or older and parents of younger children responded to a clinical effectiveness and safety survey. Effectiveness was assessed from analysis of responses to 49 questions on symptomatology plus qualitative content analyses of written reports and chart review. Adverse events (AEs) were analyzed by frequency, duration and severity. Peak InK doses ranged from 20 to 360mg per administration.

RESULTS:

Surveys were completed on 45 patients treated with InK for 3 months to 6.5 years. Almost all patients were "much" to "very much" improved clinically and in ratings of social function and academic performance. Significant reductions were reported in all symptom categories. There were 13 reports of persistent AEs, none of which resulted in discontinuation. Acute emergence reactions were sporadically observed in up to 75%, but were mild and of brief duration.

LIMITATIONS:

Retrospective review from a single practice without placebo control with potential for response and recall bias.

CONCLUSIONS:

InK every 3-4 days at sub-anesthetic doses appeared to be a beneficial and well-tolerated treatment. Use of InK may be considered as a tertiary alternative in treatment refractory cases. Randomized control trials are warranted.

KEYWORDS:

Fear of Harm Phenotype; Intranasal ketamine; Pediatric bipolar disorder; Treatment resistant mood disorder

PMID:
28866299
DOI:
10.1016/j.jad.2017.08.081
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center